TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31758520

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 31758682

Group type: EXPERIMENTAL
Intervention: DAAO method with phenylalanine intake of 15 mg · kg-1 · d-1 during early pregnancy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: DAAO method with phenylalanine intake of 21 mg · kg-1 · d-1 during late pregnancy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: IAAO method with phenylalanine intake of 21 mg · kg-1 · d-1 during late pregnancy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Previous adult male requirement
Number of subjects: 23
Study: 31758773

Group type: EXPERIMENTAL
Intervention: CardioCoach intervention (n=15)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual care control (n=10)
Number of subjects: 25
Study: 31759037

Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stent (LAMS) placement
Number of subjects: 328
Study: 31760599

Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 210

Group type: COMPARATOR
Intervention: Degludec
Number of subjects: 210
Study: 31760711

Group type: EXPERIMENTAL
Intervention: Angiotensin Receptor Blockers (ARBs)
Number of subjects: 3328

Group type: COMPARATOR
Intervention: Angiotensin-Converting Enzyme Inhibitors (ACEIs)
Number of subjects: 3328

Group type: COMPARATOR
Intervention: No ACEI/ARB use
Number of subjects: 3328
Study: 31760835

Group type: EXPERIMENTAL
Intervention: CPX-351 induction/consolidation
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7 + 3/5 + 2 chemotherapy
Number of subjects: 0
Study: 31760881

Group type: EXPERIMENTAL
Intervention: Treatment Satisfaction Questionnaire, 9 items (TSQM-9)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Morisky Medication-Taking Adherence Scale (MMAS-4)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Brief Illness Perception Questionnaire (B-IPQ)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Dyspnea score
Number of subjects: 401
Study: 31761724

Group type: EXPERIMENTAL
Intervention: Patient-derived organoids (PDOs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemoradiation (NACR)
Number of subjects: 0
Study: 31761939

Group type: EXPERIMENTAL
Intervention: Obese boys (zBMI > +2SD)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control group (660 healthy boys, -2SD < zBMI ≤ +2SD)
Number of subjects: 218
Study: 31761940

Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D) with HbA1c > 8.5%
Number of subjects: 123
Study: 31762387

Group type: EXPERIMENTAL
Intervention: Alemtuzumab additional Course 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alemtuzumab additional Course 4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alemtuzumab additional Courses 3 and 4
Number of subjects: 0
Study: 31763491

Group type: EXPERIMENTAL
Intervention: 36-ingredient micronutrient supplement
Number of subjects: 135

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 135
Study: 31764446

Group type: EXPERIMENTAL
Intervention: Psychotic Depression Assessment Scale (PDAS)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Presence of psychotic symptoms
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Psychotic Depression Assessment Scale (PDAS) total score
Number of subjects: 65
Study: 31764725

Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 31764746

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight (LMW) heparin plus aspirin (n=93)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Aspirin alone (n=94)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Urinary PlGF concentrations at mid-pregnancy (22-26 weeks of gestation)
Number of subjects: 187
Study: 31765020

Group type: EXPERIMENTAL
Intervention: Detection of Eikenella corrodens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Severe periodontitis with detection of 11 periodontal pathogens
Number of subjects: 0
Study: 31765473

Group type: EXPERIMENTAL
Intervention: Pro Seal® with erythritol air-polishing
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Pro Seal® with polishing with brush and prophy paste (Cleanic®)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Opal® Seal™ with erythritol air-polishing
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Opal® Seal™ with polishing with brush and prophy paste (Cleanic®)
Number of subjects: 96
Study: 31765809

Group type: EXPERIMENTAL
Intervention: New Atrial Tachyarrhythmia (ATA)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation (AF)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Supraventricular Tachycardia (SVT)
Number of subjects: 1500
Study: 31766869

Group type: EXPERIMENTAL
Intervention: Cementless THA with Delta ceramic bearings
Number of subjects: 76
Study: 31766870

Group type: EXPERIMENTAL
Intervention: ThrombEmb group (patients with intraventricular thrombus or embolism)
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: ThrombEmb group
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: Risk score based on clinical parameters
Number of subjects: 1676
Study: 31767018

Group type: EXPERIMENTAL
Intervention: Adenosine stress (140 microg/kg/min infusion)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Rest (following intravenous contrast bolus 0.05 mmol/kg, gadobutrol)
Number of subjects: 41
Study: 31767197

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol compliance
Number of subjects: 0
Study: 31767463

Group type: EXPERIMENTAL
Intervention: VAX-ID® intradermal injection technique
Number of subjects: 0
Study: 31767533

Group type: EXPERIMENTAL
Intervention: Very-accelerated partial breast irradiation (vAPBI) using single fraction of multicatheter interstitial high-dose rate brachytherapy (MIB) at a dose of 16 Gy.
Number of subjects: 26
Study: 31767578

Group type: EXPERIMENTAL
Intervention: Polymorphisms of genes related to vitamin D metabolism and transportation
Number of subjects: 18000
Study: 31767579

Group type: EXPERIMENTAL
Intervention: Microbial colonisation of the proximal intestinal remnant identified using 16S rRNA sequence analysis and quantified using real-time PCR.
Number of subjects: 0
Study: 31767583

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (EST) + laparoscopic cholecystectomy (LC)
Number of subjects: 2700

Group type: EXPERIMENTAL
Intervention: Laparoscopic common bile duct exploration (LCBDE) + laparoscopic cholecystectomy (LC)
Number of subjects: 2700

Group type: EXPERIMENTAL
Intervention: Laparoscopic transcystic common bile duct exploration (LTCBDE) + laparoscopic cholecystectomy (LC)
Number of subjects: 2700
Study: 31767586

Group type: EXPERIMENTAL
Intervention: Preconception women with RBC folate levels
Number of subjects: 8045

Group type: EXPERIMENTAL
Intervention: Early-pregnancy women with RBC folate levels
Number of subjects: 8045
Study: 31767591

Group type: EXPERIMENTAL
Intervention: Multicomponent preoperative and intraoperative intervention including systematic information, preoperative screening, nutrient supplementation, physical exercise, medication review, blood management, carbohydrate loading, orientation aids, and geriatric anaesthesia concept
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 240
Study: 31768187

Group type: EXPERIMENTAL
Intervention: Dynamic network biomarkers (DNBs) of TCM syndromes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytokine profiling and isobaric tags for relative and absolute quantitation (iTRAQ)
Number of subjects: 0
Study: 31768261

Group type: EXPERIMENTAL
Intervention: Individualized follow-up through a smartphone application (app) on a weekly basis for one year.
Number of subjects: 113

Group type: COMPARATOR
Intervention: Usual care including general advice regarding physical activity, exercise, and diet.
Number of subjects: 113
Study: 31768262

Group type: EXPERIMENTAL
Intervention: 150,000 IU loading dose vitamin D
Number of subjects: 96

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 96
Study: 31768386

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg b.i.d. (OCTAVE Induction 1)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg b.i.d. (OCTAVE Sustain)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg b.i.d. (OCTAVE Sustain)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (OCTAVE Induction 1)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (OCTAVE Sustain)
Number of subjects: 101
Study: 31768930

Group type: EXPERIMENTAL
Intervention: Lung function (measured by forced expiratory volume in the first second - FEV1)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Control group (COPD only patients)
Number of subjects: 520
Study: 31769309

Group type: EXPERIMENTAL
Intervention: empagliflozin
Number of subjects: 0
Study: 31769793

Group type: EXPERIMENTAL
Intervention: GSK2838232 (20 mg) with cobicistat 150 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GSK2838232 (50 mg) with cobicistat 150 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GSK2838232 (100 mg) with cobicistat 150 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GSK2838232 (200 mg) with cobicistat 150 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GSK2838232 (≥50 mg) with cobicistat 150 mg
Number of subjects: 33
Study: 31770380

Group type: EXPERIMENTAL
Intervention: ZJU index
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Hepatic steatosis index (HSI)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Lipid accumulation production index (LAPI)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Visceral adiposity index (VAI)
Number of subjects: 107
Study: 31770437

Group type: EXPERIMENTAL
Intervention: BST-236 (aspacytarabine) administered intravenously once daily over 60 minutes for 6 consecutive days at doses ranging from 0.3 to 6 g/m2 per day.
Number of subjects: 26
Study: 31770616

Group type: EXPERIMENTAL
Intervention: Genotype CC of rs1333049
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Severe periodontitis
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: SNP rs3217992
Number of subjects: 933
Study: 31771557

Group type: EXPERIMENTAL
Intervention: RISE (Recovering from IPV through Strengths and Empowerment) counseling intervention
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Feedback from VHA providers
Number of subjects: 23
Study: 31771600

Group type: EXPERIMENTAL
Intervention: iCycle training (FES cycling with virtual reality biofeedback)
Number of subjects: 11
Study: 31771603

Group type: EXPERIMENTAL
Intervention: COPE intervention (Community Outreach and Patient Empowerment)
Number of subjects: 3053

Group type: COMPARATOR
Intervention: Non-COPE participants (Control)
Number of subjects: 3053
Study: 31771607

Group type: EXPERIMENTAL
Intervention: Long-term iron supplementation
Number of subjects: 0
Study: 31771619

Group type: EXPERIMENTAL
Intervention: Resuscitation by EMS Winterthur
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Shockable rhythm as first rhythm
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Deceased patients
Number of subjects: 88
Study: 31771630

Group type: EXPERIMENTAL
Intervention: Fecal microbiota composition in AS patients
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fecal microbiota composition in AS patients with increased fecal calprotectin (≥ 200 mg/kg, n=36)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dysbiosis in AS patients
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fecal microbiota composition in AS patients with normal fecal calprotectin (≤ 50 mg/kg, n=57)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fecal calprotectin levels
Number of subjects: 150

Group type: COMPARATOR
Intervention: Comparison of fecal microbiota composition
Number of subjects: 150
Study: 31771997

Group type: EXPERIMENTAL
Intervention: Doppler echocardiography for estimating pulmonary artery pressures
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Assuming eRAP of 10 mmHg
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Estimation of eRAP during exercise from resting eRAP
Number of subjects: 97
Study: 31772104

Group type: EXPERIMENTAL
Intervention: Phthalate exposure in the NICU population
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Follow-up from age 3 to 12 through ECHO programme
Number of subjects: 400
Study: 31772121

Group type: EXPERIMENTAL
Intervention: First-line HER2-targeted therapy, chemotherapy, and sequential endocrine therapy
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: Low tumor HR positivity (1%-9%)
Number of subjects: 977
Study: 31772517

Group type: EXPERIMENTAL
Intervention: Delayed PCI
Number of subjects: 1072

Group type: COMPARATOR
Intervention: Medication Therapy (MT)
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Delayed PCI (after PSM)
Number of subjects: 1072

Group type: COMPARATOR
Intervention: Medication Therapy (MT) (after PSM)
Number of subjects: 1072
Study: 31772531

Group type: EXPERIMENTAL
Intervention: Watchman device implantation during hybrid AF ablation
Number of subjects: 10
Study: 31772605

Group type: EXPERIMENTAL
Intervention: Perioperative continuation of statin therapy (CS group)
Number of subjects: 582

Group type: COMPARATOR
Intervention: No statin therapy (DS group)
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Smoking patients
Number of subjects: 582
Study: 31772766

Group type: EXPERIMENTAL
Intervention: Subretinal injection of ranibizumab after vitrectomy with ILM peeling
Number of subjects: 19
Study: 31772984

Group type: EXPERIMENTAL
Intervention: Local hyperthermia at 39°C to 43°C delivered using radiofrequency waves at 100 Mhz once a week after proton therapy.
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Proton irradiation at a dose of 70 to 72 Gy delivered at 2.0 Gy per fraction daily for 7 weeks.
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Combination of local hyperthermia and proton irradiation.
Number of subjects: 2
Study: 31773324

Group type: EXPERIMENTAL
Intervention: Preoperative IABP
Number of subjects: 181
Study: 31773439

Group type: EXPERIMENTAL
Intervention: Bevacizumab and weekly paclitaxel therapy
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Baseline CEC count
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: CEC counts at 4 weeks
Number of subjects: 251
Study: 31773794

Group type: EXPERIMENTAL
Intervention: Mini-gastric bypass
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ileal transposition
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Transit bipartition
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Surgical groups (overall)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Postoperative β-cell function
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Postprandial GLP-1 levels
Number of subjects: 120

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 120
Study: 31773973

Group type: EXPERIMENTAL
Intervention: LumiraDx INR Test
Number of subjects: 366
Study: 31774032

Group type: EXPERIMENTAL
Intervention: Non-linear amplification configurations
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Novel feature in wireless microphone systems
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (normal-hearing listeners)
Number of subjects: 30
Study: 31774125

Group type: EXPERIMENTAL
Intervention: Total 25-hydroxyvitamin D (t25-OHD)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Calculated free 25-hydroxyvitamin D (cf25-OHD)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Directly measured free 25-hydroxyvitamin D (dmf25-OHD)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Fasting insulin and HOMA-IR
Number of subjects: 203
Study: 31774522

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1200 mg/m2, later amended to 1000 mg/m2 on days 1 and 8 every 3 weeks), plus trastuzumab (8-mg/kg loading dose, then 6 mg/kg), and pertuzumab (840-mg loading dose, then 420 mg) once every 3 weeks.
Number of subjects: 45
Study: 31774688

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for up to 35 cycles
Number of subjects: 258
Study: 31774916

Group type: EXPERIMENTAL
Intervention: VARIZIG (≤125 IU/10 kg)
Number of subjects: 123
Study: 31774957

Group type: EXPERIMENTAL
Intervention: Low C-PTP and d-dimer <1000 ng/mL
Number of subjects: 2017

Group type: EXPERIMENTAL
Intervention: Moderate C-PTP and d-dimer <500 ng/mL
Number of subjects: 2017

Group type: EXPERIMENTAL
Intervention: d-dimer level 500 to 999 ng/mL
Number of subjects: 2017

Group type: COMPARATOR
Intervention: No diagnosis of pulmonary embolism and no anticoagulant therapy
Number of subjects: 2017

Group type: EXPERIMENTAL
Intervention: Diagnostic strategy with low C-PTP and d-dimer <1000 ng/mL
Number of subjects: 2017

Group type: COMPARATOR
Intervention: Alternative strategy with low C-PTP and d-dimer <500 ng/mL
Number of subjects: 2017
Study: 31775667

Group type: EXPERIMENTAL
Intervention: Appendicular lean mass measured by dual-energy X-ray absorptiometry (DXA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grade 3 to 5 chemotherapy-related toxicities
Number of subjects: 0
Study: 31775677

Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg) followed by misoprostol (400 μg, two doses 4 hrs apart)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Misoprostol alone (400 μg, two doses 4 hrs apart)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Number of subjects: 464

Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 464
Study: 31775708

Group type: EXPERIMENTAL
Intervention: Pulmonary hypertension (PH) group
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-PH group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 51
Study: 31775714

Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (median 12.0 MET-hours/week)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Work-related physical activity (median 14.0 MET-hours/week)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 602
Study: 31775838

Group type: EXPERIMENTAL
Intervention: Transabdominal intestinal ultrasonography
Number of subjects: 116
Study: 31776238

Group type: EXPERIMENTAL
Intervention: CRS patients without nasal polyps
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: CRS patients with nasal polyps
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: CRS patients
Number of subjects: 290

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 290
Study: 31776631

Group type: EXPERIMENTAL
Intervention: Chemokine receptor-4 targeted PET/CT
Number of subjects: 30
Study: 31776899

Group type: EXPERIMENTAL
Intervention: INC280 (300 mg twice daily) + buparlisib (80 mg once daily)
Number of subjects: 43

Group type: COMPARATOR
Intervention: INC280 (monotherapy)
Number of subjects: 43
Study: 31777470

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) in patients with coronary cusp fusion (27 patients)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Transcatheter aortic valve replacement (TAVR) in patients with mixed cusp fusion (44 patients)
Number of subjects: 71
Study: 31777761

Group type: EXPERIMENTAL
Intervention: Asoprisnil 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asoprisnil 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asoprisnil (both dosages)
Number of subjects: 0
Study: 31777783

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 4967

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 4967

Group type: EXPERIMENTAL
Intervention: Tofacitinib monotherapy
Number of subjects: 4967

Group type: EXPERIMENTAL
Intervention: Tofacitinib (overall)
Number of subjects: 4967

Group type: EXPERIMENTAL
Intervention: Baseline factors
Number of subjects: 4967
Study: 31778074

Group type: EXPERIMENTAL
Intervention: Crizotinib (ALK, MET & ROS1 inhibitor)
Number of subjects: 0
Study: 31778266

Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block (SAPB)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control (standard local anesthesia and sedation)
Number of subjects: 146
Study: 31778267

Group type: EXPERIMENTAL
Intervention: Capmatinib 600 mg bid capsules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg bid tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capmatinib 200 mg bid, 250 mg bid, and 450 mg bid capsules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg bid tablets/600 mg bid capsules
Number of subjects: 0
Study: 31778281

Group type: EXPERIMENTAL
Intervention: Pain EASE program (internet-delivered self-management program based on cognitive behavioral therapy)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Pain EASE program
Number of subjects: 58
Study: 31778283

Group type: EXPERIMENTAL
Intervention: SHP656 (polysialylated recombinant factor VIII)
Number of subjects: 40

Group type: COMPARATOR
Intervention: rFVIII (octocog alfa)
Number of subjects: 40
Study: 31778781

Group type: EXPERIMENTAL
Intervention: ADHD probands
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Unaffected siblings
Number of subjects: 217

Group type: COMPARATOR
Intervention: Typically developing youths
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: ADHD probands and unaffected siblings
Number of subjects: 217
Study: 31778798

Group type: EXPERIMENTAL
Intervention: Ceritinib (750 mg/day, fasted)
Number of subjects: 124
Study: 31779476

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor with Remote Monitoring
Number of subjects: 0
Study: 31779517

Group type: EXPERIMENTAL
Intervention: Centralized Direct-Mail Colorectal Cancer Screening Approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 31779564

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 5005
Study: 31779699

Group type: EXPERIMENTAL
Intervention: DynaMesh®-Parastomal (intra-abdominal onlay mesh)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Conventional colostomy without mesh
Number of subjects: 204
Study: 31779864

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 2997